Tesamorelin vs CJC-1295: Two GHRH Analogues, Opposite Histories
Last updated
Tesamorelin and CJC-1295 act on the same receptor and could hardly have more different biographies: one became an approved pharmaceutical, the other never left the investigational stage. Comparing them is a lesson in how molecules with near-identical pharmacology can end up on opposite sides of the regulatory map. This page reads that comparison from a laboratory research perspective. Nothing here is medical advice, and the research materials discussed are not medicinal products.
What are tesamorelin and CJC-1295?
Tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group on the N-terminus, a modification that protects the peptide from rapid enzymatic degradation. A medicinal product containing tesamorelin was authorised in the US in 2010 for a specific indication, which makes it the rare compound in this catalog with an approved pharmaceutical formulation somewhere in the world.
CJC-1295 takes the opposite structural approach: instead of protecting the full hormone, it keeps only the active GHRH(1-29) fragment and hardens it with four amino-acid substitutions, with an optional albumin-binding DAC group for extended kinetics. It has published human pharmacokinetic data and no marketing authorisation anywhere.
How do their mechanisms differ?
Mechanistically the honest answer is: barely. Both are GHRH receptor agonists that amplify the amplitude of endogenous secretion pulses while leaving pulsatility intact, which is the property that distinguishes the whole GHRH class from direct hormone administration. The differences are engineering choices: full sequence versus fragment, N-terminal protection versus internal substitutions, and native kinetics versus the optional DAC extension. For receptor pharmacology, the two are close substitutes; for pharmacokinetic study design, they are distinct tools.
What does the published evidence show?
Tesamorelin carries the deepest clinical evidence of any GHRH analogue: the phase 3 programme published in 2007 reported reductions in visceral adipose tissue with IGF-1 kept within the physiological range, and later work extended the documentation to muscle and liver fat endpoints. CJC-1295’s published human record is the early pharmacokinetic and pharmacodynamic work of Teichman and colleagues, sustained GH and IGF-1 elevations after single doses, with no pivotal trials ever conducted. One molecule finished the full development road; the other documented its pharmacology and stopped.
| Tesamorelin | CJC-1295 | |
|---|---|---|
| Structure | Full GHRH(1-44), N-terminal hexenoyl group | GHRH(1-29) fragment, 4 substitutions, optional DAC |
| Human evidence | Completed phase 3 programme | Early PK/PD studies only |
| Approved medicine | In the US, specific indication | Nowhere |
| WADA status | Named example, S2, prohibited | Named example, S2, prohibited |
Which research applications does each suit?
In the laboratory the two molecules answer slightly different questions on the same axis. Tesamorelin is the reference GHRH-receptor ligand when comparability with the clinical literature matters, because its published record is the deepest in the class. CJC-1295 is the flexible engineering platform: fragment-based, available with or without the DAC clock, suited to designs that need either a clean pulse or sustained exposure. Both serve as GHRH-side inputs in axis studies pairing a GHRH analogue with a GHRP such as ipamorelin.
What is the regulatory status?
The two compounds sit at opposite ends of the same regulatory section. Tesamorelin is the active substance of a medicinal product authorised in the US; there is no EU marketing authorisation, and the research material supplied under a research use only framework is not that medicinal product, is not a medicine, and is not for human or veterinary use. CJC-1295 has no authorisation anywhere. In sport, the WADA Prohibited List names both compounds explicitly as examples under section S2, GHRH analogues; both are prohibited for athletes at all times, and the live list is the binding reference.
Research sourcing and quality checks
Both compounds are available in our catalog as research reagents: tesamorelin, CJC-1295 without DAC and CJC-1295 with DAC. Where a batch has been tested, its report is published in the lab reports archive and linked from the product page. What a proper certificate should contain is covered in our guide on reading a certificate of analysis, and both molecules are placed in the wider landscape in our evidence-tier ranking.
Conclusion
Same receptor, opposite histories: tesamorelin took the full pharmaceutical road and carries the class’s deepest clinical record; CJC-1295 stopped at pharmacology and became the flexible research tool. For laboratory buyers the comparison is mostly a comparison of documentation depth, and the practical rules do not change: both are prohibited in sport, neither research material is a medicine, and the batch paperwork is worth exactly as much as the archive behind it.
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM 2007. PubMed
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006. PubMed
- WADA Prohibited List, section S2, current edition. wada-ama.org